title: [Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study].
abstract: OBJECTIVE
  Surgical resection is still a mainstay of the treatment of Crohn's disease (CD). However, recurrence is the rule. The aim of the present study was to evaluate CD recurrence in a series of patients who underwent surgical resection with subsequent treatment with azathioprine (AZA) or mesalazine (5-ASA) and to identify the factors associated with recurrence.
  
  
  METHODS
  The medical records of patients with CD who underwent bowel resection during a 4-year period were reviewed. Only patients who received AZA or 5-ASA as prophylaxis for recurrence were included.
  
  
  RESULTS
  Thirty-three patients treated with AZA and 16 treated with 5-ASA were included. Endoscopic recurrence was found in 8.6% of the AZA group and in 87.5% of the 5-ASA group (p <0.001). Clinical recurrence occurred in 31.2% of patients in the 5-ASA group and in none in the AZA group (p=0.004). The accumulated probability of both clinical and endoscopic recurrence was significantly lower in the AZA group (p=0.0025 and p=0.005, respectively). Factors associated with a greater risk of endoscopic recurrence were termino-terminal anastomosis and 5-ASA treatment. The only factor associated with clinical recurrence was 5-ASA treatment.
  
  
  CONCLUSIONS
  AZA seems to be more effective than 5-ASA in the prevention of postsurgical endoscopic recurrence of CD. Prospective studies with long-term follow-up are required to establish the true utility of AZA in the prophylaxis of CD recurrence.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. domenech@ns.hugtip.scs.es
authors.forename: E
authors.initials: E
authors.lastname: Domènech
authors.forename: L
authors.initials: L
authors.lastname: Scala
authors.forename: I
authors.initials: I
authors.lastname: Bernal
authors.forename: E
authors.initials: E
authors.lastname: García-Planella
authors.forename: A
authors.initials: A
authors.lastname: Casalots
authors.forename: M
authors.initials: M
authors.lastname: Piñol
authors.forename: M
authors.initials: M
authors.lastname: Esteve-Comas
authors.forename: E
authors.initials: E
authors.lastname: Cabré
authors.forename: J
authors.initials: J
authors.lastname: Boix
authors.forename: M A
authors.initials: MA
authors.lastname: Gassull
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D011184:Postoperative Period; D012189:Retrospective Studies; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D019804:Mesalamine; D001379:Azathioprine